Downward price pressures on Sellas Life Sciences (NASDAQ: SLS) stock are typically driven by the inherent financial risks and binary volatility associated with clinical-stage biopharmaceutical companies. Negative or delayed clinical trial updates, capital-raising dilution through secondary share offerings, and broader market rotations away from pre-revenue biotech equities frequently weigh heavily on the stock's valuation.